- Conditions
- Anterior Cruciate Ligament Rupture
- Interventions
- IPACK block
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 890
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Litifilimab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Huntington Beach, California + 38 more
- Conditions
- Alcoholic Hepatitis
- Interventions
- Anakinra and Zinc, Prednisone, Placebos
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- ianalumab, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 15
- States / cities
- Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Interventions
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone, Placebo+Standard Care+dobutamine or milrinone
- Drug
- Lead sponsor
- Scios, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 14
- States / cities
- Stanford, California • Tampa, Florida • Chicago, Illinois + 11 more
- Conditions
- Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
- Interventions
- Pentoxifylline, Placebo, Tocopherol
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
- Conditions
- Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
- Interventions
- cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11,145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Anderson, South Carolina
- Conditions
- Heart Transplant
- Interventions
- tocilizumab, Placebo, Standard of Care Triple IS
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- IFNα-Kinoid, Placebo, ISA 51 VG
- Biological · Other
- Lead sponsor
- Neovacs
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 8 more
- Conditions
- Infections, Meningococcal
- Interventions
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 3,657 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
- Conditions
- Sars-CoV2, COVID-19
- Interventions
- Favipiravir, Placebo, Standard of care treatment
- Drug · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Nasal Polyps
- Interventions
- Fevipiprant 150 mg, Fevipiprant 450 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
- Interventions
- Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
- Drug
- Lead sponsor
- APR Applied Pharma Research s.a.
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- Fullerton, California • Irvine, California • Miami, Florida + 6 more
- Conditions
- Esophageal Neoplasms
- Interventions
- Pembrolizumab, Placebo, Cisplatin, 5-FU
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 749 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 12
- States / cities
- West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
- Conditions
- Covid19, Multisystem Inflammatory Syndrome in Children
- Interventions
- Larazotide Acetate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Amputation, Phantom Limb Pain, Stump Pain
- Interventions
- perineural ropivicaine
- Procedure
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
- Interventions
- Pentoxifylline, Placebo, Standard Treatment
- Drug · Other · Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- COVID-19
- Interventions
- Remdesivir, RDV Placebo, Standard of Care
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
- Conditions
- Eclampsia
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Autoimmune Hepatitis
- Interventions
- zetomipzomib, placebo, zetomipzomib in open-label extension
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
- Conditions
- Depressive Disorder, Major, Suicidal
- Interventions
- SLS-002, Placebo, Standard of care, Intranasal device
- Drug · Other · Device
- Lead sponsor
- Seelos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 21
- States / cities
- Orange, California • Panorama City, California • San Diego, California + 18 more
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage 0 Hypopharyngeal Carcinoma AJCC v8, Stage 0 Nasopharyngeal Carcinoma AJCC v8, Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage I Hypopharyngeal Carcinoma AJCC v8, Stage I Laryngeal Cancer AJCC v8, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage I Nasopharyngeal Carcinoma AJCC v8, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stomatitis
- Interventions
- Best Practice, Biospecimen Collection, Cisplatin, Computed Tomography, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, MnSOD Mimetic BMX-001, Placebo Administration, Questionnaire Administration
- Other · Procedure · Drug + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 153
- States / cities
- Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more
- Conditions
- Actinic Cheilitis, Squamous Cell Carcinoma In-situ (SCC-is), Squamous Cell Carcinoma (SCC), Photodynamic Therapy (PDT), Mohs Surgery
- Interventions
- PDT prior to Mohs surgery
- Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Durham, North Carolina • Canton, Ohio